FOXP3 and neoplasm: Among CD4+ T cells, we noted no changes to the number of tumor-infiltrating FOXP3+ Tregs (Supplementary Fig. 6b), and CD4+ FOXP3- effectors in the tumor parenchyma following the combination treatment (Supplementary Fig. 6c), suggesting that only CD8+ T cells are critically implicated in the observed phenotype.